tiprankstipranks
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
US Market

Spyre Therapeutics (SYRE) Income Statement

Compare
440 Followers

Spyre Therapeutics Income Statement

Last quarter (Q3 2024), Spyre Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Spyre Therapeutics's net income was $-69.03M. See Spyre Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 886.00K$ 2.33M$ 18.74M$ 0.00$ 0.00
Gross Profit
$ -78.00K$ 365.00K$ 16.74M$ -1.62M$ -901.00K
Operating Expenses
$ 243.19M$ 87.11M$ 84.39M$ 81.48M$ 79.43M
Depreciation and Amortization
$ 964.00K$ 1.96M$ 2.00M$ 1.62M$ 901.00K
EBITDA
$ -127.82M$ -83.21M$ -63.66M$ -79.27M$ -77.35M
Operating Income
$ -242.30M$ -84.78M$ -65.65M$ -81.48M$ -80.33M
Other Income/Expenses
$ -96.51M$ 830.00K$ -11.00K$ 588.00K$ 2.08M
Pretax Income
$ -338.82M$ -83.95M$ -65.66M$ -80.89M$ -78.25M
Net Income
$ -338.79M$ -83.81M$ -65.80M$ -80.89M$ -78.25M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -46.15$ -24.86$ -25.02$ -37.89$ -61.23
Diluted EPS
$ -46.15$ -24.86$ -25.02$ -37.89$ -61.23
Weighted Average Shares Outstanding
7.34M 3.37M 2.63M 2.13M 1.28M
Weighted Average Shares Outstanding (Diluted)
7.34M 3.37M 2.63M 2.13M 1.28M
Currency in USD

Spyre Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis